Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 21 - 30 of about 174   

Articles published

GSK 1,440.00 +6.00 (0.42%)
price chart
GlaxoSmithKline plc (GSK) - Research Analysts' Weekly Ratings Changes
GlaxoSmithKline plc had its price target lowered by analysts at Credit Suisse from GBX 1,475 ($23.97) to GBX 1,400 ($22.75).
1 Reason I Wouldn't Buy GlaxoSmithKline plc Today
GlaxoSmithKline remains stuck between a rock and a hard place as allegations of improper conduct spread across its global operations continue to grow.
Related articles »  
GlaxoSmithKline plc Stock Rating Reaffirmed by Deutsche Bank (GSK)
GlaxoSmithKline plc logo GlaxoSmithKline plc (LON:GSK)'s stock had its �hold� rating restated by equities research analysts at Deutsche Bank in a research note issued to investors on Wednesday.
GlaxoSmithKline plc's Hold Rating Reaffirmed at Jefferies Group (GSK)  sleekmoney
Vedanta Resources plc PT Lowered to GBX 1200 at Deutsche Bank (VED)  Mideast Time
Related articles »  
Here's Why You Need GlaxoSmithKline plc In Your Portfolio
There's no doubt that GlaxoSmithKline's (LSE: GSK) (NYSE: GSK.US) future is uncertain. After being accused of using bribes to sell its treatments within several markets, the biotechnology giant is now under investigation by the Serious Fraud Office.
GlaxoSmithKline plc Could Be Worth 1690p!
GlaxoSmithKline Investors in GlaxoSmithKline (LSE: GSK) have had a truly dismal 2014. Shares in the pharmaceutical company are down 12% since the turn of the year, with the FTSE 100 being flat over the same time period.
Novartis Wins The Battle Over Bronchodilators Against GSK
Novartis AG ADR (NVS) reported yesterday that its once-daily Ultibro (Breezhaler) bronchodilator outperformed GlaxoSmithKline plc's (ADR) (GSK) twice-daily blockbuster Seretide (Accuhaler) bronchodilator in Phase-III trials. The results of the Phase ...
Related articles »  
3 Reasons GlaxoSmithKline plc Stock Could Rise
Like most big pharmas these days, the U.K.'s GlaxoSmithKline (NYSE: GSK ) is going through a transitory period as key medicines like Advair and Lovaza lose market share to new products.
Related articles »  
GlaxoSmithKline plc Earns Hold Rating from Jefferies Group (GSK)
GlaxoSmithKline plc logo GlaxoSmithKline plc (LON:GSK)'s stock had its �hold� rating reissued by Jefferies Group in a research note issued on Monday.
GlaxoSmithKline plc PT Lowered to GBX 1400 at Credit Suisse (GSK)
GlaxoSmithKline plc logo GlaxoSmithKline plc (LON:GSK) had its target price trimmed by Credit Suisse from GBX 1,475 ($23.93) to GBX 1,400 ($22.71) in a research note released on Monday morning.
Berenberg Bank Boosts GlaxoSmithKline plc Price Target to GBX 1575 (GSK)  sleekmoney
GlaxoSmithKline plc Price Target Cut to GBX 1400 (GSK)  Watch List News (press release)
Related articles »  
GlaxoSmithKline plc Given Neutral Rating at JPMorgan Chase & Co. (GSK)
GlaxoSmithKline plc (ADR) logo JPMorgan Chase & Co. reissued their neutral rating on shares of GlaxoSmithKline plc (NYSE:GSK) in a research report released on Thursday morning. JPMorgan Chase & Co. has also modified their ratings on a number of ...
GlaxoSmithKline plc Rating Reiterated by JPMorgan Chase & Co. (GSK)  Ticker Report
GlaxoSmithKline plc Earns Neutral Rating from JPMorgan Chase & Co. (GSK)  Intercooler
Related articles »